Edgewise Therapeutics
Molly Madden is currently employed at Edgewise Therapeutics since August 2020, where Molly holds the position of Associate Scientist. Prior to their current role, Molly worked at Biofrontiers Institute from November 2017 to August 2020, serving as an Undergraduate Research Assistant. Additionally, Molly also worked as a Teaching Assistant at University of Colorado Boulder from January 2019 to May 2019. Molly earned their Bachelor's Degree in Cell/Cellular and Molecular Biology from University of Colorado Boulder in 2020.
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.